Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M226,297Revenue (TTM) $M52,253Net Margin (%)17.6Altman Z-Score3.8
Enterprise Value $M237,344EPS (TTM) $1.3Operating Margin %27.4Piotroski F-Score5
P/E(ttm)25.7Beneish M-Score-2.9Pre-tax Margin (%)23.8Higher ROA y-yN
Price/Book10.710-y EBITDA Growth Rate %3.1Quick Ratio0.9Cash flow > EarningsY
Price/Sales4.55-y EBITDA Growth Rate %1.5Current Ratio1.2Lower Leverage y-yY
Price/Free Cash Flow20.4y-y EBITDA Growth Rate %-1.7ROA % (ttm)12.1Higher Current Ratio y-yN
Dividend Yield %3.1PEG17.1ROE % (ttm)46.1Less Shares Outstanding y-yY
Payout Ratio %74.0Shares Outstanding M6,816ROIC % (ttm)30.4Gross Margin Increase y-yN

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2016-03-31 Add0.02%$30.09 - $34.47
($31.91)
$ 33.204%Add 1.88%14,906,191
RHHBYKen Fisher 2015-12-31 Add0.01%$32.55 - $35.08
($33.69)
$ 33.20-1%Add 0.63%14,630,453
RHHBYKen Fisher 2015-09-30 Add0.02%$31.65 - $36.87
($34.69)
$ 33.20-4%Add 2.30%14,538,602
RHHBYKen Fisher 2015-06-30 Add0.8%$34.38 - $38.46
($36.09)
$ 33.20-8%Add 409.71%14,211,412
RHHBYKen Fisher 2015-03-31 Reduce$32.1 - $36.505
($34.06)
$ 33.20-3%Reduce -1.24%2,788,126
RHHBYKen Fisher 2014-12-31 Add0.07%$34.16 - $37.92
($36.33)
$ 33.20-9%Add 49.26%2,823,025
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 33.20-10%Reduce -49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 33.2012%Add 99.00%3,606,140
RHHBYKen Fisher 2013-12-31 Reduce$31.96 - $35.24
($34.16)
$ 33.20-3%Reduce -0.26%1,812,112
RHHBYKen Fisher 2013-09-30 Add$30.66 - $33.77
($31.84)
$ 33.204%Add 0.28%1,816,868
RHHBYKen Fisher 2013-06-30 Add$28.92 - $32.98
($30.95)
$ 33.207%Add 0.90%1,811,804
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.95)
$ 33.207%Sold Out0
RHHBYKen Fisher 2013-03-31 Add0.12%$25.25 - $29.3
($27.75)
$ 33.2020%Add 634.57%1,795,722
RHHBYTweedy Browne 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 33.2035%Reduce -3.04%120,548
RHHBYKen Fisher 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 33.2035%Reduce -14.81%244,460
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.99 - $24.07
($22.49)
$ 33.2048%Reduce -24.31%124,328
RHHBYKen Fisher 2012-09-30 Reduce$20.99 - $24.07
($22.49)
$ 33.2048%Reduce -7.27%286,946
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.43 - $23.14
($21.16)
$ 33.2057%Add 543.36%8,547,954
RHHBYKen Fisher 2012-06-30 Reduce-0.01%$19.43 - $23.14
($21.16)
$ 33.2057%Reduce -24.26%309,426
RHHBYKen Fisher 2012-03-31 Reduce-1.27%$20.89 - $22.5
($21.77)
$ 33.2053%Reduce -98.02%408,552
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about RHHBY:

    News about RHHBY:

    Articles On GuruFocus.com
    Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
    Invesco European Growth Fund Adds to More Than 40 Existing Stakes Apr 04 2016 
    Invesco European Growth Fund Adds to 7 Stakes Jan 26 2016 
    Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
    Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
    Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
    UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
    It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
    Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 

    More From Other Websites
    3:09 am Roche Hldg reports Phase III GALLIUM study met primary endpoint ahead of schedule May 28 2016
    Roche/Biogen Drug Gazyva Beats Rituxan In Cancer Trial May 27 2016
    Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People... May 27 2016
    Novartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were... May 25 2016
    Novartis willing to sell Roche stake without demanding premium - CEO May 25 2016
    Novartis willing to sell Roche stake without demanding premium - CEO May 25 2016
    Novartis willing to sell Roche stake without demanding premium - CEO May 25 2016
    Roche announces the first FDA-approved CMV test for use in hematopoietic stem cell transplant... May 25 2016
    Novartis Filing for MabThera Biosimilar Accepted in the EU May 24 2016
    Roche Gets Accelerated Approval for Immunotherapy Drug May 19 2016
    FDA Approves Roche Immunotherapy for Bladder Cancer May 18 2016
    Phase III Study of Genentech’s Alecensa® (Alectinib) Showed Superior Efficacy Versus Crizotinib... May 18 2016
    U.S. FDA approves Roche's immunotherapy for bladder cancer May 18 2016
    Roche receives FDA Approval for novel PD-L1 biomarker assay May 18 2016
    U.S. FDA approves Roche's immunotherapy for bladder cancer May 18 2016
    FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval for... May 18 2016
    Roche submits 510 (k) filing to FDA for Treponema pallidum assay to aid clinicians in the diagnosis... May 18 2016
    Insulet Shares Swoon on Insurer Decision, but Fair Value Is Unchanged May 11 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)